Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | NT5E | P21589 | 6/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1412239 | 0.83 | ADORA1 (0.54) | NT5EADORA2AADORA1ADORA3 | |
| SCHEMBL3001982 | 0.83 | ADORA1 (0.54) | NT5EADORA2AADORA1ADORA3 | |
| SCHEMBL4048825 | 0.74 | ADORA1 (0.39) | NT5EADORA2AADORA1ADORA3 | |
| SCHEMBL242859 | 0.72 | ADORA2A (0.45) | NT5EADORA2AADORA3 | |
| SCHEMBL242860 | 0.72 | ADORA2A (0.45) | NT5EADORA2AADORA3 | |
| SCHEMBL3891540 | 0.72 | NT5E (0.38) | NT5EADORA2AADORA1ADORA3 | |
| Acetic Acid SCHEMBL243164 | 0.71 | ADORA2A (0.44) | NT5EADORA2AADORA3 | |
| SCHEMBL1412166 | 0.71 | ADORA1 (0.51) | ADORA2AADORA1ADORA3 | |
| SCHEMBL4374282 | 0.70 | ADORA2A (0.42) | ADORA2AADORA3 | |
| SCHEMBL1412472 | 0.69 | ADORA2A (0.55) | NT5EADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2018388-A2 | BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007121924-A2 | BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |